吉非替尼脂质体对S_(180)荷瘤小鼠药效学研究  

Pharmacodynamics of gefitinib liposomes on S_(180) tumor bearing mice

作　　者：何琳[1] 马海英[1] 

机构地区：[1]中国医科大学附属第四医院药学部,沈阳110032

出　　处：《中南药学》2015年第11期1159-1162,共4页Central South Pharmacy

摘　　要：目的考察吉非替尼脂质体对S180荷瘤小鼠抗肿瘤作用及对免疫系统的影响。方法采用硫酸铵梯度法制备吉非替尼脂质体,利用透析法考察其体外释放度,以S180荷瘤小鼠为动物模型,给药剂量分别为20mg·kg-1及40 mg·kg-1,计算抑瘤率、脾脏指数及胸腺指数,并进行统计学分析。结果吉非替尼脂质体体外释放度符合Higuchi动力学模型,高剂量组的相对质量抑瘤率为72.02%,脾脏指数及胸腺指数与对照组差异均无统计学意义。结论吉非替尼脂质体对小鼠S180肿瘤有明显的抑制作用,对其免疫系统没有明显损伤。Objective To investigate the effect of gefitinib liposomes on S180 tumor and immune organs in tumor bearing mice. Methods Gefitinib liposomes were prepared by ammonium sulfate gradient method. The release rate was measured by dialysis method. The model of S180 tumor bearing mice was established to calculate the antitumor efficacy. The administration of gefitinib solutions and gefitinib liposomes were 20 mg·kg^- 1 and 40 mg·kg^- 1. The spleen index and thymus index were used for statistical analysis. Results The release rate of gefitinib liposomes in vitro fit the Higuchi model. The relative antitumor rate of high-dose gefitinib liposomes was 72.02%. Compared with the control group, there was no significant difference in the spleen index and the thymus index. Conclusion Gefitinib liposomes show obvious inhibition on S180 tumor in mice and little influence on the immune system.

关 键 词：吉非替尼 脂质体 释放度 药效学 

分 类 号：R965[医药卫生—药理学]